Skip to content
glp1.howSign in

Supportive Health

Obstructive sleep apnea

A sleep disorder in which the airway repeatedly collapses during sleep, causing brief pauses in breathing; it is closely linked to obesity.

By the glp1.how editorial teamReviewed

Obstructive sleep apnea (OSA) is a condition in which the upper airway repeatedly narrows or collapses during sleep, causing brief pauses in breathing and drops in oxygen. It can lead to loud snoring, fragmented sleep, daytime fatigue, and, over time, added strain on the heart.

OSA is strongly linked to excess weight, particularly around the neck and abdomen. Standard treatments include CPAP therapy and weight management, and tirzepatide has been approved to treat moderate-to-severe OSA in adults with obesity, based on trials showing it reduced the number of breathing interruptions during sleep.

The FDA approved Zepbound (tirzepatide) for this use on December 20, 2024, after trials showed fewer apnea and hypopnea events over 52 weeks than with placebo (FDA (external link)).

sleepobesitytirzepatide

Revision history

Updated 1 time since Jul 18, 2026 · show changes
  1. v2

    Body revised

  2. v1

    Change tracking began

Related guides

  • Sleep quality on a GLP-1: why it matters, what changes, and the sleep apnea connection · Sleep is the quiet variable in GLP-1 treatment. Short sleep can shift weight loss away from fat and toward muscle, GI side effects and hunger changes can disturb the night, and one GLP-1 medication is now FDA-approved to treat obstructive sleep apnea itself. This guide covers how sleep stages work, how treatment can affect them, and why protecting deep sleep helps protect your muscle.
  • CPAP as the weight comes off: managing sleep apnea on a GLP-1 · Tirzepatide (Zepbound) roughly halved sleep apnea severity in the SURMOUNT-OSA trials, and 42 to 50% of participants reached the trial's definition of resolution. That still left many with apnea, and the trials never tested stopping CPAP for good. This guide covers why you shouldn't retire your machine on your own, how pressure and mask fit change as weight comes off, when and how a repeat sleep test happens, and how an OSA diagnosis affects Zepbound coverage (as of September 2026).
  • Cortisol, stress, and weight on a GLP-1: what the connection really is · The "cortisol makes you fat" story is mostly overstated. Real cortisol excess, as in Cushing's syndrome, clearly drives central fat, but everyday stress does far less. On a GLP-1, cortisol matters more for muscle than for belly fat. This guide covers the evidence, how sleep affects cortisol, and why "cortisol-blocker" supplements don't hold up.
  • Protecting your bones on a GLP-1: bone density, fracture risk, and what actually helps · Losing a lot of weight usually costs a small amount of bone, mostly at the hip, and GLP-1 weight loss is no exception. So far the fracture data are reassuring and the drug itself does not look like the main cause, but the long-term evidence is thin. Here's what the bone-density and fracture studies show, who should pay the most attention, and the levers that kept bone steady in trials: resistance and impact training, protein, calcium and vitamin D, and a well-timed bone scan.
  • Physician's Choice Digestive Enzymes & 60 Billion Probiotic: are they worth it on a GLP-1? · Physician's Choice markets these two supplements together in a "Hack Your Tummy" TikTok campaign for bloating and post-meal discomfort, a real complaint for GLP-1 users. Both score 54/100 (Skip). The GI need is real, but neither label discloses per-ingredient doses (for the probiotic, per-strain CFU), the certifications cited describe the factory rather than the product, and you pay a premium for formulas you can't check against the research.
  • How GLP-1 medications affect men vs. women: what the sex differences actually are · The same GLP-1 medication doesn't act quite the same in men and women. On average women lose more weight, report more side effects, and absorb more of the drug at the same body weight, differences driven partly by estrogen and testosterone. This guide covers what the research shows about sex differences in weight loss, tolerability, blood sugar and biology, and what it means for what you should expect.

Related terms

  • Tirzepatide · A once-weekly dual GIP and GLP-1 receptor agonist made by Eli Lilly, marketed as Mounjaro for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.
  • CPAP · Continuous positive airway pressure: a bedside machine that blows gently pressurized air through a mask to hold the airway open during sleep, the standard first-line treatment for obstructive sleep apnea.
  • Zepbound · Eli Lilly's brand name for injectable tirzepatide, FDA-approved for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity.

Was this helpful?

Improve this page